Expanding the Horizons in Hereditary Angioedema

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Hereditary Angioedema Due to C1-INH Deficiency

Manifestations of HAE

Triggers for HAE Attacks

Individualizing Treatment

Individualizing Treatment (cont)

Short-Term and Preprocedural Prophylaxis

Who Is a Candidate for Long-Term Prophylaxis?

Long-Term Prophylaxis

Long-Term Prophylaxis With Androgens

Long-Term Prophylaxis With Antifibrinolytic Agents

Long-Term Prophylaxis Plasma-Derived C1-INH Concentrate: 1000 Units Twice Weekly

Long-Term Prophylaxis With Intravenously Infused C1-INH

Physician Survey on Current Trends in Long-Term HAE Prophylaxis Use

Frequency of Peripheral Vein Difficulties During the Past 6 Months

COMPACT Study Number of HAE Attacks per Month

COMPACT Study Use of Rescue Medication

Long-Term Prophylaxis Subcutaneously Injected C1-INH

Emerging Agents for Prophylactic Use

Ongoing Preclinical Research

A Comprehensive, Individualized Management Plan

Individualized, Patient-Centric Plan for Prophylaxis

Patient-Caregiver Education

Patients Should Have an Action Plan for Attacks

Concluding Remarks

Abbreviations